A citation-based method for searching scientific literature

Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Simona Frezzini, Germana Tognon, Grazia Artioli, Angiolo Gadducci, Rossella Lauria, Annamaria Ferrero, Saverio Cinieri, Andrea De Censi, Enrico Breda, Paolo Scollo, Ugo De Giorgi, Andrea Alberto Lissoni, Dionyssios Katsaros, Domenica Lorusso, Vanda Salutari, Sabrina Chiara Cecere, Eleonora Zaccarelli, Margherita Nardin, Giorgio Bogani, Mariagrazia Distefano, Stefano Greggi, Maria Carmela Piccirillo, Roldano Fossati, Gaia Giannone, Laura Arenare, Ciro Gallo, Francesco Perrone, Sandro Pignata. Int J Gynecol Cancer 2021
Times Cited: 3

List of co-cited articles
5 articles co-cited >1

Times Cited
  Times     Co-cited

Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011

A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder,[...]. N Engl J Med 2011

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer,[...]. N Engl J Med 2019

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019

A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study.
Grigoris T Gerotziafas, Ali Taher, Hikmat Abdel-Razeq, Essam AboElnazar, Alex C Spyropoulos, Salem El Shemmari, Annette K Larsen, Ismail Elalamy. Oncologist 2017

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018.
J Ferlay, M Colombet, I Soerjomataram, T Dyba, G Randi, M Bettio, A Gavin, O Visser, F Bray. Eur J Cancer 2018

PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.
J R Perry, J A Julian, N J Laperriere, W Geerts, G Agnelli, L R Rogers, M G Malkin, R Sawaya, R Baker, A Falanga,[...]. J Thromb Haemost 2010

Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis.
Irit Ben-Aharon, Salomon M Stemmer, Leonard Leibovici, Ofer Shpilberg, Aaron Sulkes, Anat Gafter-Gvili. Acta Oncol 2014

Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer.
H E Fuentes, D M Oramas, L H Paz, A I Casanegra, A S Mansfield, A J Tafur. Thromb Res 2017

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Marcello Di Nisio, Ettore Porreca, Matteo Candeloro, Michele De Tursi, Ilaria Russi, Anne Ws Rutjes. Cochrane Database Syst Rev 2016

Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment.
Norbaini Binti Abdol Razak, Gabrielle Jones, Mayank Bhandari, Michael C Berndt, Pat Metharom. Cancers (Basel) 2018

Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients.
Cecilia Becattini, Melina Verso, Andres Muňoz, Giancarlo Agnelli. Haematologica 2020

Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study.
Chiara Alessandra Cella, Giovanni Di Minno, Chiara Carlomagno, Michele Arcopinto, Anna Maria Cerbone, Elide Matano, Antonella Tufano, Florian Lordick, Biagio De Simone, Katja Sibylle Muehlberg,[...]. Oncologist 2017

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.
N Colombo, C Sessa, A du Bois, J Ledermann, W G McCluggage, I McNeish, P Morice, S Pignata, I Ray-Coquard, I Vergote,[...]. Ann Oncol 2019

Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.
Herbert I Hurwitz, Leonard B Saltz, Eric Van Cutsem, James Cassidy, Jonas Wiedemann, Florin Sirzén, Gary H Lyman, Ulrich-Peter Rohr. J Clin Oncol 2011

Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Christina Fotopoulou, Andreas duBois, Alexandros N Karavas, Ralf Trappe, Behnaz Aminossadati, Barbara Schmalfeldt, Jacobus Pfisterer, Jalid Sehouli. J Clin Oncol 2008

Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews.
Marina T Van Leeuwen, Steven Luu, Howard Gurney, Martin R Brown, Sallie-Anne Pearson, Kate Webber, Lee Hunt, Soojung Hong, Geoffrey P Delaney, Claire M Vajdic. JNCI Cancer Spectr 2020

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
Shobha Rani Nalluri, David Chu, Roger Keresztes, Xiaolei Zhu, Shenhong Wu. JAMA 2008

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017

Development and validation of a predictive model for chemotherapy-associated thrombosis.
Alok A Khorana, Nicole M Kuderer, Eva Culakova, Gary H Lyman, Charles W Francis. Blood 2008

A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score.
Melina Verso, Giancarlo Agnelli, Sandro Barni, Giampietro Gasparini, Roberto LaBianca. Intern Emerg Med 2012

Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer.
Sylvia K Haas, Mathias Freund, David Heigener, Lothar Heilmann, Bettina Kemkes-Matthes, Georg-Friedrich von Tempelhoff, Nima Melzer, Ajay K Kakkar. Clin Appl Thromb Hemost 2012

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny. Nat Rev Drug Discov 2004

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Amit M Oza, Adrian D Cook, Jacobus Pfisterer, Andrew Embleton, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes,[...]. Lancet Oncol 2015

Prediction of venous thromboembolism in cancer patients.
Cihan Ay, Daniela Dunkler, Christine Marosi, Alexandru-Laurentiu Chiriac, Rainer Vormittag, Ralph Simanek, Peter Quehenberger, Christoph Zielinski, Ingrid Pabinger. Blood 2010

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Kathleen N Moore, Michael Bookman, Jalid Sehouli, Austin Miller, Charles Anderson, Giovanni Scambia, Tashanna Myers, Cagatay Taskiran, Katina Robison, Johanna Mäenpää,[...]. J Clin Oncol 2021

ToleRability of BevacizUmab in elderly Ovarian cancer patients (TURBO study): a case-control study of a real-life experience.
Giulia Amadio, Claudia Marchetti, Emanuele Rocco Villani, Domenico Fusco, Francesca Stollagli, Carolina Bottoni, Mariagrazia Distefano, Giuseppe Colloca, Giovanni Scambia, Anna Fagotti. J Gynecol Oncol 2020

First-line therapy in ovarian cancer trials.
Tate Thigpen, Andreas duBois, Jessica McAlpine, Philip DiSaia, Keiichi Fujiwara, William Hoskins, Gunnar Kristensen, Robert Mannel, Maurie Markman, Jacobus Pfisterer,[...]. Int J Gynecol Cancer 2011

Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care.
Charles H Norell, John Butler, Rhonda Farrell, Alon Altman, James Bentley, Citadel J Cabasag, Paul A Cohen, Scott Fegan, Michael Fung-Kee-Fung, Charlie Gourley,[...]. Int J Gynecol Cancer 2020

Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials Group.
Michael Brundage, David Osoba, Andrea Bezjak, Dongsheng Tu, Michael Palmer, Joseph Pater. J Clin Oncol 2007

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
N Colombo, C Sessa, A du Bois, J Ledermann, W G McCluggage, I McNeish, P Morice, S Pignata, I Ray-Coquard, I Vergote,[...]. Int J Gynecol Cancer 2019

Real-World Evidence in Oncology: Opportunities and Limitations.
Massimo Di Maio, Francesco Perrone, Pierfranco Conte. Oncologist 2020

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
Amit M Oza, Frédéric Selle, Irina Davidenko, Jacob Korach, Cesar Mendiola, Patricia Pautier, Ewa Chmielowska, Aristotelis Bamias, Andrea DeCensi, Zanete Zvirbule,[...]. Int J Gynecol Cancer 2017

Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study.
Frédéric Selle, Nicoletta Colombo, Jacob Korach, César Mendiola, Andres Cardona, Youssef Ghazi, Amit M Oza. Int J Gynecol Cancer 2018

Relevance of randomised controlled trials in oncology.
Ian F Tannock, Eitan Amir, Christopher M Booth, Saroj Niraula, Alberto Ocana, Bostjan Seruga, Arnoud J Templeton, Francisco Vera-Badillo. Lancet Oncol 2016

Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study.
Marcia Hall, Gianfilippo Bertelli, Louise Li, Clare Green, Steve Chan, Chit Cheng Yeoh, Jurjees Hasan, Rachel Jones, Agnes Ograbek, Timothy J Perren. Int J Gynecol Cancer 2020

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Sandro Pignata, Domenica Lorusso, Florence Joly, Ciro Gallo, Nicoletta Colombo, Cristiana Sessa, Aristotelis Bamias, Vanda Salutari, Frédèric Selle, Simona Frezzini,[...]. Lancet Oncol 2021

Multiple VEGF family members are simultaneously expressed in ovarian cancer: a proposed model for bevacizumab resistance.
Arne R M van der Bilt, Ate G J van der Zee, Elisabeth G E de Vries, Steven de Jong, Hetty Timmer-Bosscha, Klaske A ten Hoor, Wilfred F A den Dunnen, Harry Hollema, Anna K L Reyners. Curr Pharm Des 2012

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016

Role of HIF-1 in Cancer Progression: Novel Insights. A Review.
Aldo Pezzuto, Elisabetta Carico. Curr Mol Med 2018

Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma.
Kentaro Nakayama, Atsuko Kanzaki, Kohkichi Hata, Hidetaka Katabuchi, Hitoshi Okamura, Kohji Miyazaki, Manabu Fukumoto, Yuji Takebayashi. Cancer Lett 2002

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.